CG
Live price temporarily unavailable.
Price history
Cognition Therapeutics (CGTX) is a Health Care company. Latest news and coverage below.
IPO: October 8, 2021 · $12.00 offering · NASDAQ · View IPO details →
Cognition Therapeutics net income history (FY2020–FY2025)
Net income
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Operating income | −$17.4M | −$28.6M | −$43.6M | −$50.7M | −$54.0M | −$47.8M |
| Net income | −$7.84M | −$11.7M | −$21.4M | −$25.8M | −$34.0M | −$23.5M |
| EPS (diluted) | −$23.76 | −$3.13 | −$0.91 | −$0.86 | −$0.86 | −$0.32 |
| Balance sheet | ||||||
| Cash and equivalents | $5.19M | $54.7M | $41.6M | $29.9M | $25.0M | $36.8M |
| Total assets | $7.12M | $59.1M | $50.4M | $35.2M | $30.2M | $48.4M |
| Total liabilities | $19.9M | $7.86M | $10.2M | $10.7M | $11.5M | $14.1M |
| Shareholders' equity | −$68.2M | $51.3M | $40.2M | $24.5M | $18.8M | $34.3M |
| Cash flow | ||||||
| Operating cash flow | −$3.43M | −$3.63M | −$18.5M | −$16.0M | −$28.5M | −$24.6M |
| Capital expenditure | $10.0K | $27.0K | $171.0K | $147.0K | $4.00K | — |
| Free cash flow | −$3.44M | −$3.66M | −$18.7M | −$16.2M | −$28.5M | — |
Net income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$14.5M | −$10.7M | −$13.8M | −$14.0M | −$6.38M | −$13.7M | −$8.82M | −$7.74M |
| Net income | −$9.94M | −$7.84M | −$8.48M | −$6.73M | −$4.93M | −$3.34M | −$4.57M | −$3.93M |
| EPS (diluted) | −$0.25 | −$0.16 | −$0.14 | −$0.11 | −$0.06 | −$0.01 | −$0.05 | −$0.04 |
| Balance sheet | ||||||||
| Cash and equivalents | $22.0M | $25.0M | $16.4M | $10.7M | $39.3M | $36.8M | $31.1M | $34.0M |
| Total assets | $27.6M | $30.2M | $23.5M | $19.6M | $43.4M | $48.4M | $36.1M | $38.9M |
| Total liabilities | $13.1M | $11.5M | $11.2M | $12.6M | $6.87M | $14.1M | $6.23M | $5.87M |
| Shareholders' equity | $14.5M | $18.8M | $12.3M | $7.03M | $36.5M | $34.3M | $29.9M | $33.0M |
| Cash flow | ||||||||
| Operating cash flow | −$6.85M | −$8.38M | −$9.88M | −$5.62M | −$5.65M | −$3.44M | −$5.54M | −$3.05M |
| Capital expenditure | $0 | $1.00K | — | — | — | — | — | — |
| Free cash flow | −$6.85M | −$8.38M | — | — | — | — | — | — |
From Cognition Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Cognition Therapeutics
- Headquarters
- Purchase, New York From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International